Nigeria’s leading pharmaceutical company, Fidson Healthcare Plc, has announced a groundbreaking partnership with Chinese firms to build a $100 million drug manufacturing plant in Lagos, Nigeria’s commercial capital.
The move comes as the country grapples with a severe shortage of essential medicines, driven by surging inflation, currency volatility, and the departure of several multinational pharmaceutical companies from the Nigerian market.
Fidson Healthcare signed a cooperation memorandum with Jiangsu Aidea Pharmaceutical Co., PharmaBlock Sciences Nanjing Inc., and the China-Africa Development Fund, committing to the construction of the state-of-the-art facility within the next 30 months. The planned facility is expected to significantly boost local drug production and reduce Nigeria’s dependence on imported medicines, especially antiretrovirals used in HIV treatment.
Tekedia Mini-MBA edition 15 (Sept 9 – Dec 7, 2024) has started registrations; register today for early bird discounts.
Tekedia AI in Business Masterclass opens registrations here.
Join Tekedia Capital Syndicate and invest in Africa’s finest startups here.
Fidson stated in a release. “By integrating our expertise and experience in the field of innovative drugs, we are confident in bringing greater well-being to patients. The complementary strengths of all parties will inject new vitality into the healthcare sector.”
The plant will focus on producing much-needed medications, including antiretroviral drugs to address Nigeria’s significant HIV burden. According to the Joint United Nations Programme on HIV/AIDS, Nigeria has an estimated 2 million people living with the virus, with about 1,400 new infections reported weekly last year. The National Agency for the Control of AIDS also reported that approximately 1.2 million children have been orphaned due to the disease.
Filling the Void Left by Multinationals
Nigeria, home to 220 million people, currently imports all its antiretroviral drugs, severely limiting availability. The withdrawal of major pharmaceutical companies such as GSK Plc and Sanofi SA, due to economic instability and operational challenges, has exacerbated the crisis, leaving patients vulnerable to opportunistic infections.
The costs of drugs manufactured by the existing companies went to the roof, becoming unaffordable to majority of Nigerians whose spending power have been significantly squeezed by high inflation.
Fidson Healthcare, which previously manufactured over-the-counter drugs for GSK, has rapidly expanded its product lineup to address the gap in the drug supply chain. Since June of last year, the company has introduced more than 16 new products, bolstering its portfolio to meet the growing demand for locally produced medications.
Fidson is believed to be stepping in to fill the void left by the exit of multinational pharmaceutical companies, ensuring that Nigerians have access to essential medications. This move is expected to reduce reliance on imported drugs and to build a sustainable pharmaceutical ecosystem in Nigeria.
“The upcoming manufacturing facility will become a hub for pharmaceutical excellence, leveraging the Lekki Free Trade Zone’s strategic location and comprehensive infrastructure to foster economic growth and healthcare improvement,” the Corporate Services Manager of Fidson, Temitope Akindele, said.
However, Nigeria’s pharmaceutical industry faces numerous challenges, including high inflation, a volatile currency, and a lack of reliable electricity, all of which contribute to the rising cost of imported drugs and raw materials. Compounding the exodus of multinationals, unfriendly business environment has also deterred investment from global pharmaceutical giants, pushing the responsibility of local drug manufacturing onto domestic firms like Fidson.
The planned facility, therefore, represents not just a business expansion but a critical intervention in Nigeria’s healthcare system. It aims to enhance the local production of life-saving medicines and improve the availability of affordable drugs to millions of Nigerians.
As the project gets underway, expectations are high that the $100 million investment will not only alleviate the current shortage of medicines but also set the stage for a more self-reliant and resilient pharmaceutical industry in Nigeria. For Fidson, the partnership represents an opportunity to solidify its role as a key player in the local market and a champion of health equity.
Fidson’s proactive approach reflects a broader trend among local companies stepping up to address critical healthcare needs in Nigeria. As multinationals exit the market, the onus is increasingly on domestic firms to bridge the gap and ensure that the country’s healthcare system can withstand future challenges.